Empiric Guideline Therapy for Simple Urinary Tract Infection at Outpatient Clinics: A Prospective Observational Study Empiric Guideline Therapy for Simple Urinary Tract Infection at Outpatient Clinics
Main Article Content
Keywords
simple urinary tract infection, empirical antimicrobials in UTI, urine culture and susceptibility test, common uropathogens, antibiotics resistance bacteria in UTI
Abstract
Background: Community-acquired urinary tract infection is a widespread problem encountered in the outpatient clinics of most hospitals. UTI has various clinical presentations; some are simple UTIs that can be managed with outpatient antibiotics. The current treatment of UTI is empirical, based on the limited and predictable spectrum of etiological microorganisms.
Objectives: To collect information on the susceptibility tests of microorganisms in simple urinary tract infections (UTIs) and outline the best empiric antimicrobial prescribed for them.
Methods: A total of 117 patients from 14 to 70 years of age (mean age = 43.61years, standard deviation = + 24.5) received the care of our surgical and urological outpatient clinics in Alnuman Teaching Hospital, Baghdad, Iraq, between March 1, 2019, and September 1, 2020. The patients who were showing symptoms of simple uncomplicated UTI and were prescribed empiric antibacterial treatment and requested for a sample of midstream urine for culture and sensitivity tests were enrolled in this prospective study. The susceptibility test for (ciprofloxacin, trimethoprim, gentamycin, and ceftriaxone) was performed using the Kirby–Bauer disc diffusion method. The data were input into SPSS 22.0 for statistical analysis. Pearson’s chi-squared test was used to compare parameters. The data have been presented as the number of variables (n) and percentages (%). Statistical significance was set at P < 0.05.
Results: The frequencies of isolated uropathogens were as follows: E. coli, n = 65 (77.4%); Klebsiella spp., n = 9 (10.7%), Proteus spp., n = 3 (3.57%), Enterobacter spp., n = 3 (3.57%)., Staphylococcus spp., n = 2 (2.38%)., Pseudomonas spp., n = 1 (1.19%), and Candida spp., n = 1 (1.19%). The resistance rates of the most prevalent microorganisms were E. coli isolates to trimethoprim, ciprofloxacin, gentamycin, and ceftriaxone. The lower resistance rates to ceftriaxone in E. coli isolates (29.7%) was not clinically significant, with p < 0.05. Gentamycin showed significant sensitivity and resistance rates of 58.3% and 33.3% respectively, among the antimicrobials used (p < 0.05). The clinical effectiveness of empirical antimicrobial use in the treatment of simple UTIs showed no statistically significant correlation with P < 0.05.
Conclusions: Trimethoprim and ciprofloxacin should not be used in empirical therapy for UTIs because of their increased resistance rates. A review of the local guidelines should be considered.
References
2. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015 May;13(5):269-84.
3. Aypak C, Altunsoy A, Düzgün N. Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: a prospective observational study. Ann Clin Microbiol Antimicrob. 2009 Dec;8(1):1-7.
4. Nzalie RN, Gonsu HK, Koulla-Shiro S. Bacterial etiology and antibiotic resistance profile of community-acquired urinary tract infections in a Cameroonian city. Int J Microbiol. 2016 Sep 7.
5. Cunha MA, Assunção GL, Medeiros IM, Freitas MR. Antibiotic resistance patterns of urinary tract infections in a northeastern Brazilian capital. Rev Inst Med Trop São Paulo. 2016 Feb 23;58.
6. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014 Aug 28;6:25-64.
7. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010 Jun; 8(6):423-35.
8. Logan NZ, Karp BE, Tagg KA, Burns-Lynch C, Chen J, Garcia-Williams A, Marsh ZA, O’Laughlin K, Plumb ID, Schroeder MN, Webb HE. 130. increase in multidrug resistance (2011–2018) and the emergence of extensive drug resistance (2020) in shigella Sonnei in the United States. Open Forum Infect Dis. 2020 Oct;7(Suppl 1): S195-S195.
9. Dibua UM, Onyemerela IS, Nweze EI. Frequency, urinalysis and susceptibility profile of pathogens causing urinary tract infections in Enugu State, southeast Nigeria. Rev Inst Med Trop São Paulo. 2014 Jan;56:55-9
10. Adegun PT, Odimayo MS, Olaogun JG, Emmanuel EE. Comparison of uropathogens and antibiotic susceptibility patterns in catheterized ambulant middle-aged and elderly Nigerian patients with bladder outlet obstruction. Turk J Urol. 2019 Jan;45(1):48.
11. Rodloff A, Bauer T, Ewig S, Kujath P, Müller E. Susceptible, intermediate, and resistant–the intensity of antibiotic action. Dtsch Ärztebl Int. 2008 Sep;105(39):657.
12. Lee DS, Lee SJ, Choe HS. Community-acquired urinary tract infection by Escherichia coli in the era of antibiotic resistance. BioMed Res Int. 2018 Sep 26;2018.
13. Konapa LA, Vesalapu V, Kolakota RK, Mugada V. Pregnancy and hormonal effects on urinary tract infections in women: a scoping review. Int J Res Rev. 2018;5(10):407-20.
14. Adams LG. Treatment of urinary tract infection (UTI): Guidelines for sporadic and recurrent UTI.
15. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar 1;52(5):e103-20.
16. Frantchez V, Pintos M, Bataglino MN, Torales M, Díaz ÁA. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.
17. Sasirekha B. Prevalence of ESBL, AmpC β-lactamases and MRSA among uropathogens and its antibiogram. EXCLI J. 2013;12:81.
18. Yekani M, Baghi HB, Sefidan FY, Azargun R, Memar MY, Ghotaslou R. The rates of quinolone, trimethoprim/sulfamethoxazole and aminoglycoside resistance among Enterobacteriaceae isolated from urinary tract infections in Azerbaijan, Iran. GMS Hyg Infection Control. 2018;13.
19. Stapleton AE, Wagenlehner FM, Mulgirigama A, Twynholm M. Escherichia coli resistance to fluoroquinolones in community-acquired uncomplicated urinary tract infection in women: a systematic review. Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00862-20..
20. Tavakoli-Far B, Pourhatami F, Gharavi MJ. Prevalence and antimicrobial resistance properties of 3 Extended-spectrum beta-lactamases (ESBL) producing 4 Escherichia coli isolated from the cases of Urinary Tract 5 Infections 6.
21. Arredondo-García JL, Amábile-Cuevas CF. High resistance prevalence towards ampicillin, co-trimoxazole and ciprofloxacin, among uropathogenic Escherichia coli isolates in Mexico City. The Journal of Infection in Developing Countries. 2008 Oct 1;2(05):350-3.
22. Mulder M, Verbon A, Lous J, Goessens W, Stricker BH. Use of other antimicrobial drugs is associated with trimethoprim resistance in patients with urinary tract infections caused by E. coli. Eur J Clin Microbiol Infect Dis. 2019 Dec;38(12):2283-90.
23. Li D, Reid CJ, Kudinha T, Jarocki VM, Djordjevic SP. Genomic analysis of trimethoprim-resistant extraintestinal pathogenic Escherichia coli and recurrent urinary tract infections. Microb Genom. 2020 Dec;6(12).
24. Fasugba O, Gardner A, Mitchell BG, Mnatzaganian G. Ciprofloxacin resistance in community-and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies. BMC Infectious Dis. 2015 Dec;15(1):1-6.
25. Aypak C, Altunsoy A, Düzgün N. Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: a prospective observational study. Ann Clin Microbiol Antimicrob. 2009 Dec;8(1):1-7.
26. Ozyurt M, Haznedaroğlu T, Sahiner F, Oncül O, Ceylan S, Ardic N, Erdemoğlu A. Antimicrobial resistance profiles of community-acquired uropathogenic Escherichia coli isolates during 2004-2006 in a training hospital in Istanbul. Mikrobiyol Bul. 2008 Apr 1;42(2):231-43.
27. Wang SS, Ratliff PD, Judd WR. Retrospective review of ceftriaxone versus levofloxacin for treatment of E. coli urinary tract infections. Int J Clini Pharm. 2018 Feb;40(1):143-9.
28. Sharma N, Gupta A, Walia G, Bakhshi R. Pattern of antimicrobial resistance of Escherichia coli isolates from urinary tract infection patients: a three-year retrospective study. J Appl Pharm Sci. 2016 Jan;6(01):062-5.
29. Mostafavi SN, Rostami S, Nejad YR, Ataei B, Mobasherizadeh S, Cheraghi A, Haghighipour S, Nouri S, Pourdad A, Ataabadi P, Almasi N. Antimicrobial resistance in hospitalized patients with community acquired urinary tract infection in Isfahan, Iran. Arch Iran Med. 2021 Mar 1;24(3):187-92.
30. Sia CS, Ananda‐Rajah MR, Adler NR, Yi‐Wei B, Liew D, Tong EY, Aung AK. Renal safety of short‐term empiric gentamicin therapy in aged patients. Australas J Ageing. 2018 Sep;37(3):227-31.
31. Ryanto S, Wong M, Czarniak P, Parsons R, Travers K, Skinner M, Sunderland B. The use of initial dosing of gentamicin in the management of pyelonephritis/urosepsis: a retrospective study. Plos One. 2019 Jan 23;14(1):e0211094.
32. Ekmen S, Doğan E. Evaluation of gentamicin ototoxicity in newborn infants: a retrospective observational study. Int J Pediatr. 2021 Mar 1;9(3):13137-44.
33. Hain G, Goldbart A, Sagi O, Ben-Shimol S. High rates of antibiotic nonsusceptibility in gram-negative urinary tract infection in children with risk factors occurring in the preceding month: considerations for choosing empiric treatment. Pediatr Infect Dis J. 2021 Jul 1;40(7):639-44.
34. Gums J. To fight antibiotic resistance, we need to fight bad prescribing habits.[Internet] Australia. The Conversation. 2016.
35. McEwen LN, Farjo R, Foxman B. Antibiotic prescribing for cystitis: how well does it match published guidelines?. Ann Epidemiol. 2003 Jul 1;13(6):479-83.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.